SUVN-502

DB06140InvestigationalSmall molecule

SUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer’s...

Mechanism: Pharmacologically active on 5-hydroxytryptamine receptor 6
Curator reviewed
Primary indication: Investigated for use/treatment in neurologic disorders.Curator reviewed
Formula / weight: C₂₁H₂₄BrN₃O₃S · 478.41 g/mol (avg)
Also known as: Masupirdine
Code names: SUVN-502

Resolves to

Compound

UNII8XZ281AO3GCAS701205-60-9ChEMBLCHEMBL4117187

Structure

InChIKeyGWCYPEHWIZXYFZ-UHFFFAOYSA-NSMILESCOC1=CC=C2N(C=C(CN3CCN(C)CC3)C2=C1)S(=O)(=O)C1=CC=CC=C1Br

Targets

P50406HTR6

What you can answer from here — as of September 14, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with SUVN-502, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account